|
Website:
http://www.neose.com
Phone: +1 215 315-9000 |
Address:
102 Witmer Road
Horsham, PENNSYLVANIA 19044 |
Company Description
Neose Technologies Incorporated. The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins .Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. Develop proprietary drugs, focusing primarily on therapeutic proteins
Key People
| President & Chief Executive | George J. Vergis |
| Senior Vice President & Chief Financial Officer | A. B. Davis |
| Senior Vice President, Secretary & General Counsel | Esq Debra J. Poul |
Related Business Topics
0-9 |
A |
B |
C |
D |
E |
F |
G |
H |
I |
J |
K |
L |
M |
N |
O |
P |
Q |
R |
S |
T |
U |
V |
W |
X |
Y |
Z
N
Neose Technologies
Neose is building a leadership position in the enzymatic synthesis of carbohydrates by continued discovery and development of novel synthesis technologies.
www.neose.com
Neose is building a leadership position in the enzymatic synthesis of carbohydrates by continued discovery and development of novel synthesis technologies.
www.neose.com
